2026 Annual Meeting of Shareholders

ANNUAL
SHAREHOLDER
MEETING 2026

ATTENDEES
QUESTION &
VOTING
PROCESS

MEETING AGENDA
B U S I N E S S O F T H E M E E T I N G
CHAIR'S ADDRESS
Dame Alison Stewart
CHIEF EXECUTIVE OFFICER'S ADDRESS
Scott Johnson
RESOLUTIONS
1. That Paul Munro be elected as a Director
2. That pursuant to NZX Listing Rule 2.11.1, the maximum aggregate
amount of remuneration payable by the Company to Directors be
increased from $309,000 per annum to $340,000 per annum
3. That the Directors be authorised to fix the remuneration of the
auditors for the ensuing year
OTHER BUSINESS

BOARD OF DIRECTORS
DAME ALISON STEWART
Chair, Independent Non-
executive Director
Member of People &
Performance Committee
AMELIA (AIMEE)
MCCAMMON
Independent Non-
executive Director
Chair of People &
Performance
Committee; Member of
Audit & Risk Committee
DR BARRY
RICHARDSON
Independent Non-
executive Director
Member of Audit & Risk
Committee; Member of
People & Performance
Committee
PAUL MUNRO
Independent Non-
executive Director
Chair of Audit & Risk
Committee
ANITA JOHANSEN
Non-executive Director

FY26 SUMMARY
$
14.7M
RE V E N U E
▲16% on prior year
$
1.8M
U N DE R L YI N G E B I T D A*
▲83% on prior year
$
1.6M
U N DE R L YI N G NPA T *
▲90% on prior year
$
8.5M
CA S H & D E POS I T S
At 31 March 2026

CEO
ADDRESS
SCOTT JOHNSON
Chief Executive Officer

EXECUTIVE
TEAM
SCOTT JOHNSON
Chief Executive Officer (CEO)
RICHARD WINGHAM
Chief Financial Officer (CFO)
JENNIFER WALKER
Chief Revenue Officer (CRO)
DR JOHN HALE
Chief Technology Officer (CTO)
ASHLEIGH CHILDS
Head of People, Culture & PMO
MELISSA DRYSDALE
Head of Quality

GLOBAL MARKET SNAPSHOT
PROBIOTIC DIETARY SUPPLEMENT MARKET
Market size in USD Billion · CAGR 11.74%
$12.52B
2025
$13.98B
2026
$24.35B
2031
Source: Mordor Intelligence
GLOBAL PROBIOTIC DIETARY SUPPLEMENTS
MARKET BY REGION (2024)
22% Europe
25% North America
37.8% Asia-Pacific
5.4% Rest of World
10% Middle East & Africa
Source: Mordor Intelligence, 2025

FY26 FINANCIAL PERFORMANCE
REVENUE
▲16% on prior year
$m
11.5
FY24
12.6
FY25
14.7
FY26
UNDERLYING EBITDA*
▲83% on prior year
$m
0.8
FY24
1.0
FY25
1.8
FY26
UNDERLYING NPAT*
▲90% on prior year
$m
0.6
FY24
0.8
FY25
1.6
FY26
* Underlying EBITDA and NPAT adjust for a $0.9m one-off supply chain cost increase during FY26.

FY26 SUMMARY
REVENUE BY REGION
FY26
FY25








EMEA
New Zealand
Asia Pacific (excl. NZ)
North America
REVENUE BY CHANNEL
FY26




FY25


B2B
B2C
CASH GENERATED FROM
OPERATIONS
▼133% on prior year
$m
1.1
1.8
(0.6)
FY24FY25FY26
FY26 reflects investment in inventory
during the period.
20
Publications relating to
our strains
17
Conferences attended or
presented at
2
New patents granted
Progression of China regulatory
project to examination stage

REVENUE & MARKET PERFORMANCE -B2B
$
9.9M
B2 B REVENU E ▲2 2%
•Ingredient $7.3m, up 17% -the primary
growth driver.
•Asia Pacific up $0.9m -new South
Korea customer
•Royalty $1.3m, up 17%
•Private label $1.3m, up 67% -China
offline expansion
B2B REVENUE (NZ$M)
8.0
FY24
8.1
FY25
9.9
FY26
FY26 B2B REVENUE BY SALES CHANNEL



Ingredient
Royalty
Private label

REVENUE & MARKET PERFORMANCE -B2C
$
4.8M
B2 C R EVENU E
•New Zealand Wholesale –up 20% -strong
product ranging and growing focus on
dental
•Amazon US up 5%, despite tariffs
•BLIS Webstore up 12%
•CBEC $0.3m, down from $0.6m in FY25
-pricing reset to align with new China
partners and managed exit of smaller
diagouresellers from market
B2C REVENUE (NZ$M)
3.5
FY24
4.5
FY25
4.8
FY26
FY26 B2C REVENUE BY CHANNEL




NZ Wholesale
Amazon
BLIS Webstore
China CBEC

INTELLECTUAL PROPERTY & MARKET RISKS
IP MATTER RESOLVED
•Patent issue with Bluestone Pharma (BSP) & Lactosan
GmbH resolved in July 2025
•Relevant patents now jointly owned by BLIS & BSP; all claims
released
•Five-year extension to the BSP supply agreement secured
NEW PATENTS GRANTED
•Antiviral applications of Streptococcus salivarius K12 and M18
•Enhanced formulations combining BLIS strains with specific
prebiotic sugars
CHINA REGULATORY
•Key clinical trial, central to China regulatory strategy,
commenced in 2HY26 and is expected to be complete in 1HY27.
PROBI
•Revised Technology License and Distribution Agreement
with ProbiAB in October 2025
•Introduces pet nutrition into Probi’slicensed territories

STRATEGIC FOCUS & EXECUTION
CONTINUED FOCUS ON
CORE: BLIS K12&
BLIS M18
EXPANDED PROBI
AGREEMENT —USA,
CANADA, EMEA & PET
NUTRITION
CHINA CLINICAL TRIAL
UNDERWAY —
COMPLETION EXPECTED
1H27
CONSUMER-INSIGHT-
DRIVEN R&D, NPD AND
BRAND REFRESH

FY27 STRATEGIC PLAN
O U R P U R P O S E
Being the best at developing probiotic solutions for the health and wellbeing of global consumers
OUR IMPACT
PEOPLEPROFIT
CUSTOMER
OUR VISION
We are recognised globally as the preferred partner and leader in oral probiotic innovation
HOW WE DELIVER
CREATE TECHNOLOGY BLOCKSGROW GLOBAL PARTNERSHIPS
BUILD BRAND BLIS
RIGHT PEOPLE
SECURE SUPPLY
QUALITY PROCESSES & SYSTEMS
OUR VALUES
OUR MANA
CUSTOMER FIRST
MAKE IT HAPPENONE TEAM

ESG & CULTURE
B CORP CERTIFICATION
MYGREEN LAB
CERTIFICATION
MAINTAINED
'LEADING AT BLIS'
LEADERSHIP
PROGRAMME
0
LTI’S -7 YEARS LTI FREE
HEALTH & SAFETY
EXTERNAL AUDIT
COMPLETED

SUPPLY CHAIN
ONE-OFF COST OF $0.9M IMPACTED FY26 EARNINGS
ADDITIONAL FERMENTATION PARTNER

CLOSING & OUTLOOK
UNAUDITED RESULTS FOR THE QUARTER ENDED
30 JUNE 2026 (1Q27)
$5.1M
RE V EN UE
$1.1M
E B IT D A
FY27 PRIORITIES
•Accelerate growth in key markets with the right partners
•Advance R&D, new product development and IP protection
•Invest in building the BLIS brand: Masters of the Oral
Microbiome
•Maintain financial discipline for sustainable, profitable growth
FY27 OUTLOOK
•FY27 full year revenue growth of 10-15%

QUESTIONS
W A I T F O R T H E M I C R O P H O N E

ATTENDEES QUESTION PROCESS
?
QUESTION BOX
Select "Ask a Question" in the online portal,
type your question, and submit it to the
Chair.

RESOLUTIONS
W A I T F O R T H E M I C R O P H O N E

ATTENDEES VOTING PROCESS
+
VOTING CARD
Select "Get a Voting Card" in the online
portal, then cast your vote For, Against
or Abstain on each resolution.

R E S O L U T I O N 1
THAT PAUL MUNRO BE ELECTED AS
A DIRECTOR OF THE COMPANY
W A I T F O R T H E M I C R O P H O N E
State your name and whether you are a shareholder or
proxy holder

R E S O L U T I O N 2
THAT PURSUANT TO NZX LISTING RULE 2.11.1, THE
MAXIMUM AGGREGATE AMOUNT OF REMUNERATION
PAYABLE BY THE COMPANY TO DIRECTORS BE
INCREASED FROM $309,000 PER ANNUM TO $340,000
PER ANNUM
W A I T F O R T H E M I C R O P H O N E
State your name and whether you are a shareholder or
proxy holder

R E S O L U T I O N 3
THAT THE DIRECTORS BE AUTHORISED TO
FIX THE REMUNERATION OF THE AUDITORS
FOR THE ENSUING YEAR
W A I T F O R T H E M I C R O P H O N E
State your name and whether you are a shareholder or proxy holder

GENERAL BUSINESS

DISCLAIMER
I NF OR MA TI ON
The information in this presentation is an overview and does not contain all
information necessary to make an investment decision. It is intended to constitute a
summary of certain information relating to the performance of BLIS Technologies
Limited (“Company” or “BLIS”). The information in this presentation is of a general
nature and does not purport to be complete. This presentation should be read in
conjunction with the Company's other periodic and continuous disclosure
announcements, which are available at nzx.com.
N OT FI NA N CI A L PR OD U CT A D VI CE
This presentation is for information purposes only and is not financial or investment
advice or a recommendation to acquire BLIS securities and has been prepared
without taking into account the objectives, financial situation or needs of individuals.
The Company, its directors and employees do not give or make any
recommendation or opinion in relation to acquiring or disposing of shares. In making
an investment decision, investors must rely on their own examination of the
Company, including the merits and risks involved. Investors should consult their own
legal, tax, business and/or financial advisers in connection with any acquisition of
securities.
FU T U RE P ER FOR M AN CE
This presentation may contain certain ‘forward-looking statements’, for example
statements concerning the development and commercialisationof new products,
regulatory approvals, customer adoption and results of future clinical studies.
Forward-looking statements can generally be identified by the use of forward-
looking words such as ‘expect’, ‘anticipate’, likely’, ‘intend’, ‘could’, ‘may’, ‘predict’,
‘plan’, ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, and
other similar expressions. The forward-looking statements contained in this
presentation are not guarantees or predictions of future performance and involve
known and unknown risks and uncertainties and other factors, of which are beyond
the control of the Company and may involve significant elements of subjective
judgement and assumptions as to future events which may or may not be correct.
There can be no assurance that actual outcomes will not materially differ from these
forward-looking statements. A number of important factors could cause actual
results or performance to differ materially from the forward-looking statements. The
forward-looking statements are based on information available to the Company as at
the date of this presentation. Except as required by law or regulation (including the
NZX Main Board Listing Rules), the Company undertakes no obligation to provide
any additional or updated information whether as a result of new information, future
events or results or otherwise.
N O REP RE S ENT AT IO N
This presentation may contain information from third parties believed to be reliable;
however, no representations or warranties are made as to its accuracy or
completeness.

THANK YOU
P R O B I O T I C S M A D E T O M A T T E R

---

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
27 August 2026
BLIS Technologies Limited
Annual Shareholder Meeting 2026

Chair’s Address
Slide 1 - Introduction
Good morning, and welcome everyone to the BLIS Technologies Limited Annual Shareholder
Meeting for 2026. My name is Alison Stewart, and I am Chair of the Board for BLIS Technologies.
On behalf of my fellow directors, our Chief Executive, Scott Johnson, and all of the BLIS team, it is my
pleasure to welcome you all here today in person and to those of you attending online.
This is my first Annual Shareholder Meeting as Chair, having taken on the role in October 2025. I
would like to acknowledge Geoff Plunket, who stood down as Chair last October after just over four
years in the role, and who retired from the Board in March 2026 after eight years of service. Geoff's
leadership was instrumental in advancing BLIS' strategic growth and strengthening our governance,
and on behalf of the Board and the wider BLIS team, I thank him sincerely.
Slide 2 – Question and Voting Process
Today we are providing both an in person and online attendance option for shareholders. It is
pleasing once again to have so many shareholders join us online today, and to see so many of you in
person.
When it comes to voting: For our shareholders in attendance here you may vote as usual on the
voting card provided to you at the registration desk when you arrived. For shareholders online, you
will be able to cast your vote online by pressing the “Get a voting card” button and validating
yourself using your shareholder or proxy number. Please note that only shareholders, proxy holders
or shareholder company representatives may vote.
Please refer to the virtual meeting online portal guide or contact the team at MUFG Corporate
Markets on 0800 200 220 if you require any assistance.
Shareholders online will also be able to ask questions by clicking the “ask a Question” button. I
encourage shareholders who have questions to send their questions through as soon as possible.
I am pleased to say that the meeting has been properly called and there is a quorum present.
We will be using slides during the meeting. For those of you online you will be able to see these and
follow along. They have also been posted to the NZX and are available on the BLIS website.

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
A quick Health & Safety note - for those of you here with us, in the unlikely event of an emergency
the building needs to be evacuated, please evacuate via the emergency exit doorways indicated.
Follow the signs to the main staircase and out to the front entrance by the nearest assembly point.
Slide 3 – Meeting Agenda
The agenda for this morning will include an overview from myself of the company’s performance for
the year to 31 March 2026. Scott Johnson, our CEO, will then provide you with a deeper review of
the results, and on progress against our strategic plan.
There will then be an opportunity for shareholders to ask questions. We will first take questions
from those in attendance here today and then any questions posted online that have not already
been covered by responses to previous answers.
Following this we will then move to the formal business of the meeting. At that point I will outline
the process for the discussion and voting on the three resolutions set out in the agenda.
At the meeting’s conclusion, for those of you here with us we would be delighted if you would join
the directors and the BLIS team for light refreshments and further discussions.
Slide 4 – Board of Directors - Introductions
Before reviewing the company’s performance, I would first like to introduce our Board. Their profiles
are available on the BLIS Technologies website and are also included within the annual report.
Myself, Alison Stewart, joined the Board in September 2018 and became Chair in October 2025. I
bring substantial experience in research, development and innovation within the international
biotechnology industry.
Aimee McCammon was appointed to the Board in October 2021, is MD of Pic’s Peanut Butter based
in Nelson, with a background in advertising, marketing and governance.
Dr Barry Richardson joined the board in 2018. Barry has a science background and brings both BLIS
specific and international biotechnology and nutritional dairy industry experience to the board.
Paul Munro was appointed to the Board in March 2026 and is currently Chair of the Audit and Risk
Committee. Paul brings extensive financial, commercial and governance experience, including his
prior role with Deloitte as a Corporate Finance Partner and CEO of Christchurch City Holdings
Limited, and his current directorships of Scales Corporation Limited, New Zealand King Salmon
Investments Limited, Orion NZ Limited and Tait International Limited. Paul is standing for election
today under Resolution 1.

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
Anita Johansen joined the Board in January 2024. She is currently VP of Global Innovation for
Symrise Care and Wellness and was previously CEO of Probi. Anita has a background in
pharmaceuticals and has held leadership positions in various global consumer healthcare companies
and is a board member of both the International Association of Probiotics (IPA) and IPA Europe.
Slide 5 – FY26 Summary - Results
It is pleasing to report that BLIS had strong revenue and underlying earnings growth for the year
ended 31 March 2026. Revenue for the year was $14.7m, a 16% increase on the prior year.
Underlying EBITDA was $1.8m, up 83%, and underlying net profit after tax was $1.6m, up 90%.
These underlying results adjust for a one-off supply chain cost increase of $0.9m incurred during the
year. On a reported basis, EBITDA was $0.9m, compared to $1.0m in FY25, and net profit after tax
was $0.7m, compared to $0.8m in FY25.
The financial year was marked by disciplined commercial execution, meaningful progress on key
strategic partnerships, and the resolution of the significant intellectual property matter that had
carried over from FY25.
Revenue growth was underpinned by strong growth across our B2B ingredient and private label
revenues, together with continued B2C momentum, particularly in the New Zealand wholesale
channel.
BLIS continues to be in a strong financial position, with cash and short-term deposits of $8.5m at 31
March 2026. This is down from $9.7m in FY25, reflecting an investment in inventory during the
period
Management is currently refreshing the company’s long term growth plan and capital requirements
for presentation to the Board in December. Following the Board’s consideration, we expect to
update shareholders on this plan.
While these long term capital requirements are yet to be confirmed, the Directors have agreed not
to propose a distribution.
In reviewing the capital structure of the company, the Directors announced yesterday to invoke the
Minimum Shareholding Provisions set out in the NZX Listing Rules and the Company's constitution.
BLIS recognises that it is difficult for some shareholders to sell small parcels of shares because the
cost of brokerage can be disproportionately high relative to the value of their shareholding.
Maintaining a large number of small shareholdings also involves ongoing registry and administration
costs for BLIS. The Board considers that the implementation of a minimum holding requirement will
assist BLIS to maintain an efficient share register.
Thanks for your attention I will now hand over to our CEO Scott Johnson.

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz

CEO Address
Slide 6 – CEO Address (Handover to Scott)
Thank you, Alison,
Good morning everyone, and thank you for joining us today, whether you're here in person or
participating online.
On behalf of the Leadership Team, I'd like to thank all of our shareholders for your continued
support of BLIS.
FY26 was an important year for our business. It was a year where we demonstrated that BLIS can
continue to grow while remaining disciplined in how we operate.
Although our reported earnings were impacted by a significant one-off increase in supply chain
costs, the underlying performance of the business strengthened materially.
During the year we grew revenue by 16%, strengthened profitability on an underlying basis,
expanded our intellectual property portfolio, progressed our China regulatory programme, further
strengthened our partnership with Probi and finished the year with a strong balance sheet.
Just as importantly, we continued investing in the long-term capabilities that will support future
growth.
Today I'd like to take you beyond the headline result and explain what is happening inside BLIS,
where we are seeing growth, and how we are continuing to build a stronger and more scalable
business.
Slide 7 - BLIS Executive Team
Before discussing the business in more detail, I'd like to introduce the BLIS Leadership Team, who
are here today representing all areas of the business.

● Richard Wingham – Chief Financial Officer
● Jennifer Walker – Chief Revenue Officer
● Dr John Hale – Chief Technology Officer
● Ashleigh Childs – Head of People, Culture and PMO
● Melissa Drysdale – Head of Quality

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz

Together they bring expertise across science, commercial, finance, operations, quality and people.
Every result we are discussing today reflects the work of this team and the wider BLIS organisation.
I'd like to thank them, and all of our employees, for their commitment throughout FY26.

Slide 8 – Global market snapshot

Before discussing our own performance, it's useful to step back and consider the market we operate
in.
The global probiotic dietary supplement market continues to experience strong structural growth.
Consumers are increasingly focused on preventative health, microbiome science and clinically
supported products – trends that align directly with BLIS' strengths.
The market is estimated at approximately $14 billion in 2026 and is projected to reach more than
$24 billion by 2031. Asia-Pacific remains the largest regional market, followed by North America and
Europe.
BLIS already has commercial positions and established partners across all three regions. Our
opportunity is not simply to participate in a growing category; it is to convert our science,
intellectual property and partnerships into sustainable commercial growth.
Slide 9 – FY26 Financial performance
Turning now to our financial performance.
As Alison has outlined, FY26 represented another year of strong revenue growth, with revenue
increasing 16% to $14.7 million.
Underlying EBITDA increased 83% to $1.8 million and underlying net profit after tax increased 90%
to $1.6 million. These underlying measures adjust for the one-off $0.9 million increase in supply
chain costs and provide a clearer view of the operating performance of the business.
We also finished the year with cash and deposits of $8.5 million. That balance sheet strength gives
us flexibility to continue investing in science, product development, strategic partnerships and the
capabilities required for future growth.
For me, the important point is that the underlying business strengthened while we continued to
invest for the future.
Slide 10 – FY26 Financial performance
This slide provides more insight into the quality of that performance.

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
Revenue is becoming increasingly diversified across both geography and channels. EMEA
represented 31% of FY26 revenue, New Zealand 30%, Asia-Pacific excluding New Zealand 24%, and
North America 15%.
Our channel mix also continued to move toward B2B, which represented 68% of revenue in FY26,
with B2C at 32%.
Operating cash flow reflects a deliberate investment in inventory to protect continuity of supply
following the one-off raw ingredient price increase.
Beyond the financial metrics, we continued investing in the foundations of the business. During the
year our science team contributed to 20 publications relating to our strains, attended or presented
at 17 conferences, and we secured two new patents. Our China regulatory programme also
continued to advance.
These are important investments because they strengthen the science, IP and market access that
underpin BLIS' long-term competitive position.
Slide 11 – Revenue and Market Performance – B2B
B2B remains the largest part of our business and was the primary driver of growth in FY26.
B2B revenue increased 22% to $9.9 million and now represents around 68% of total company
revenue.
Ingredient revenue was $7.3 million, up 17%, supported by strong EMEA orders, new customer
launches and the establishment of a new South Korean customer.
Royalty revenue increased 17% to $1.3 million, while private label revenue increased 67% to $1.3
million, led by growth from our Chinese partner into the offline professional health market.
What is encouraging here is that growth is not dependent on a single customer, market or revenue
stream. We are increasingly building multiple sources of commercial growth around our core science
and strains.
Slide 12 – Revenue and Market Performance – B2C
Turning to our consumer business.
B2C complements our B2B strategy by building the BLIS brand, creating direct consumer
engagement and providing valuable consumer insights that can also support our wider commercial
proposition.

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
B2C revenue was $4.8 million. New Zealand wholesale was the standout performer, growing 20%,
with strong product ranging and an increasing focus on dental products. Amazon US continued to
grow despite tariffs, and our BLIS webstore also grew.
China cross-border e-commerce reduced following a deliberate pricing reset and the managed exit
of smaller daigou resellers as part of our evolving China strategy.
We are focused on building a healthier and more sustainable consumer business rather than
pursuing revenue at any cost.
Slide 13 – Intellectual Property and Market Risks
One of the important achievements of FY26 was strengthening the foundations of the business.
We resolved the intellectual property matter with Bluestone Pharma and Lactosan, with the relevant
patent applications now jointly owned, and secured a five-year extension to the existing BSP supply
agreement.
We also secured two new patents covering antiviral applications of BLIS K12 and BLIS M18 and
enhanced formulations combining our probiotic strains with specific prebiotic sugars.
Our China regulatory pathway continued to advance, with the key clinical trial underway, and we
expanded our agreement with Probi across the USA, Canada and certain EMEA markets, as well as
into pet nutrition.
Collectively, these developments strengthen BLIS' competitive position and create additional
pathways for future commercial growth.
Slide 14 – Strategic focus and Execution
Our priorities remain clear and consistent.
We continue to focus on our core strains, BLIS K12 and BLIS M18; deepen our partnership with Probi;
progress the China regulatory pathway; and invest in research, innovation and the BLIS brand.
What I hope you can see from the progress we've made is that BLIS is becoming a stronger and more
scalable business.
We are building more routes to market, deeper global partnerships, a stronger technology and IP
base, greater supply resilience and a brand that can support both our B2B and consumer businesses.
Those are the building blocks we believe can support the next stage of BLIS' growth.

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
Slide 15 – BLIS Strategic plan
Our strategic plan provides the framework for how we build that business.
Our purpose remains being the best at developing probiotic solutions for the health and wellbeing of
global consumers, and our vision is to be recognised globally as the preferred partner and leader in
oral probiotic innovation.
We deliver on this by creating technology blocks, growing global partnerships and building the BLIS
brand, underpinned by the right people, secure supply, and quality processes and systems.
These are not separate initiatives. They are interconnected capabilities that allow us to turn our
science into sustainable commercial growth at greater scale.
Our values – Our Mana, Customer First, Make It Happen and One Team – continue to guide how we
work and how we build the company.
Slide 16: ESG and Culture
Strong and sustainable businesses are built on strong cultures.
During FY26 we progressed our B Corp assessment, maintained our MyGreen Lab GREEN
certification, continued investing in leadership capability through our Leading at BLIS programme,
and achieved seven years without a lost-time injury.
We also completed a full external health and safety audit, with all recommended actions addressed.
We were also proud to be shortlisted for the 2026 Best Places to Work Awards and to win the Forbes
Packaging Marketing Award for our BLIS M18 campaign at the Natural Health Products NZ Industry
Awards – external recognition of both the strength of our culture and the quality of our work.
I'd like to thank every member of the BLIS team for their contribution to these outcomes and for
helping create a culture we are proud of.
Slide 17: Supply Chain
The one-off raw ingredient price increase reduced reported earnings during FY26, but securing
continuity of supply was the right decision for the business and our customers.
Management responded by increasing inventory and progressing work with an additional
fermentation partner to strengthen long-term supply resilience.

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
Combined with the extended BSP supply agreement, these actions broaden our supply options and
leave BLIS in a stronger operational position.
As the business grows, secure and scalable supply becomes increasingly important, and this remains
a key area of focus.
Slide 18 – Closing and outlook
I'll finish by looking briefly at FY27.
For the quarter ended 30 June 2026, BLIS reported unaudited revenue of $5.1 million and EBITDA of
$1.1 million.
Looking ahead, we remain focused on accelerating growth in key markets through the right partners,
advancing research and development and IP protection, investing in the BLIS brand, strengthening
our operating capabilities, and maintaining financial discipline.
Our expectation remains for FY27 revenue growth of between 10 and 15 percent.
We enter FY27 with confidence. Demand for science-backed oral probiotics continues to grow, and
BLIS is well placed to benefit from that growth.
FY26 demonstrated that the underlying business is strengthening. We have more routes to market,
stronger partnerships, an expanding science and IP base, and a strong balance sheet from which to
invest.
Our focus now is on converting those foundations into sustainable, profitable growth and continuing
to build a larger and more scalable BLIS.
Finally, I'd like to thank our employees, customers, commercial partners and shareholders for your
continued support.
FY26 was a strong step forward for BLIS, and we look forward to updating you on our continued
progress throughout FY27.
Thank you.